Dual-target CAR-T for relapsed/refractory myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy that targets two proteins (BCMA and CD19) on myeloma cells. It may help patients whose myeloma has come back or stopped responding to previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have multiple myeloma that has relapsed or not responded to at least one prior treatment, including a proteasome inhibitor, an immunomodulatory drug, or a CD38 antibody.
- Your myeloma cells must test positive for BCMA and/or CD19.
- You are between 18 and 70 years old.
- You are healthy enough to perform daily activities (ECOG score 0-2) and expected to live more than 3 months.
- Your blood counts, liver, kidney, and heart function meet minimum levels (e.g., hemoglobin at least 60 g/L, creatinine no more than 2 times upper limit of normal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
This trial tests a new type of immunotherapy called CAR-T cells that target two proteins (BCMA and FcRL5) on myeloma cells. It is for people whose myeloma has returned or not responded to other treatments.
This trial tests a lab-made immune cell therapy (CAR-T) designed to attack a protein called BCMA on myeloma cells. It’s for adults whose multiple myeloma or related plasma cell disease has come back or didn’t respond to prior treatment, aiming to improve cancer control.
This early trial tests a new CAR-T cell treatment targeting three proteins (CD19, CD22, and BCMA) on myeloma cells. It's for people whose myeloma came back or didn't respond to at least three prior treatments.
This Phase 1/2 study tests a BCMA-targeting CAR-T cell therapy for people with relapsed or refractory multiple myeloma or related plasma cell diseases. It may help by using your own immune cells, engineered to recognize a specific target on cancer cells.
This trial tests a new cell therapy (CAR-T) that targets two proteins on myeloma cells for patients whose cancer has returned or not responded after at least three prior treatments. It aims to see if this therapy is safe and effective.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.